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Abstract: Ceftaroline fosamil (ceftaroline) was recently approved for the treatment of 
  community-acquired pneumonia (CAP) and complicated skin infections. This newly devel-
oped cephalosporin possesses a broad spectrum of activity against gram-positive and gram-
negative bacteria. Most importantly, ceftaroline demonstrates potent in vitro antimicrobial 
activity against multi-drug resistant Streptococcus pneumoniae and methicillin-resistant 
strains of   Staphylococcus aureus. In two Phase III, double-blinded, randomized, prospective 
trials (FOCUS 1 and FOCUS 2), ceftaroline was shown to be non-inferior to ceftriaxone for 
the treatment of CAP in hospitalized patients. Ceftaroline exhibits low resistance rates and a 
safety profile similar to that of other cephalosporins. In this review, we will evaluate the phar-
macological characteristics, safety, antimicrobial properties, and efficacy of ceftaroline and its 
applications in the treatment of CAP.
Keywords: s. pneumoniae, s. aureus, cephalosporins, pneumonia, ceftaroline, community 
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Introduction
The ideal antibiotic for the treatment of community-acquired pneumonia (CAP) should 
have the following characteristics: (a) a spectrum of activity that covers the major-
ity of pathogens associated with this infection; (b) documented clinical efficacy and 
safety in a variety of patient populations; and (c) cost-effectiveness. Current guidelines 
recommend stratifying patients into groups depending on the presence of specific risk 
factors and evaluating health care utilization history to select appropriate empirical 
antimicrobial therapy.1 The implementation of these guidelines has greatly increased 
the rate of treatment success for CAP.2,3 Despite this, treatment failures continue to 
exist and the need for more effective therapies is a consequence of two main issues: the 
emergence of antimicrobial resistance and newly emerging pathogens causing CAP.
The rise in the detection of multi-drug resistant Streptococcus pneumoniae (S. pneu-
moniae) (MDRSP) has caused significant concern.4,5 This pathogen displays elevated 
minimum inhibitory concentrations (MIC) for penicillin and cephalosporins, and often 
demonstrates cross resistance with other classes, including macrolides, tetracycline 
and trimethoprim/sulfamethoxazole; although the fluoroquinolone class is relatively 
spared.6 There is controversy regarding how in vitro resistance translates into clinical 
outcomes. Studies evaluating the mortality of patients affected by MDRSP compared to 
more susceptible strains of S. pneumoniae have shown conflicting results.7–10 However, 
some of these studies were limited by confounding factors including age, comorbidi-
ties, and severity of illness.8 Nevertheless, there are reports that patients with MDRSP 
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may have more complications, longer hospital lengths of stay, 
and greater therapeutic failures.6,11,12
Staphylococcus aureus (S. aureus) is a dynamic pathogen 
that continues to pose a great challenge to clinicians treating 
patients with CAP and other infections. Methicillin-resistant 
strains of S. aureus (MRSA) infections cause significant 
mortality and contribute to increased health care costs.13–15 
Most worrisome are data demonstrating a rise in CAP due to 
MRSA.16–19 Community-associated MRSA characteristically 
belongs to the USA-300 pulse-field electrophoresis type, 
containing the Panton-Valentine leukocidin gene, and is an 
important cause of necrotizing CAP.20,21 Compared to other 
sites of infection, CAP caused by MRSA of the USA-300 
type is associated with worse clinical outcomes.22 Due to 
these emerging trends of resistance and the need to treat a 
wider range of patient populations, newer therapies should 
be explored for the treatment of MRSA, and other resistant 
gram-positive bacteria.23
The USA Federal Drug Administration (FDA) has 
recently approved ceftaroline fosamil (TEFLAROTM,   Forest 
Pharmaceuticals Inc, St Louis, MO) for the treatment of 
CAP and complicated skin infections. This antibiotic pos-
sesses a broad spectrum of activity against gram-positive 
and gram-negative bacteria. Most importantly, ceftaroline 
has antimicrobial activity against MDRSP and MRSA. We 
will review the pharmacological characteristics, safety, anti-
microbial properties, and effectiveness of ceftaroline and its 
applications in the treatment of CAP patients.
Mechanisms of action
Ceftaroline is a fifth-generation cephalosporin with a 
mechanism of action similar to that of other commercially 
available β-lactams.24–26 It binds to penicillin binding pro-
teins (PBPs) and prevents the synthesis of peptidoglycan, an 
essential component in bacterial cell walls.24–26 The drug’s 
activity against S. aureus and MRSA is due to its high affin-
ity for PBP1–3 and PBP2a.24–26 Additionally, ceftaroline 
binds to PBP3, PBP1A, PBP2X, PBP1B, and PBP2A/B, 
which are primary targets for S. pneumoniae, including 
resistant strains.24–26
Microbiologic activity
Ceftaroline has demonstrated activity against a broad spec-
trum of gram-positive pathogens (Table 1). Several studies 
evaluating the in vitro activity of ceftaroline have been car-
ried out (Table 2).27–33 A surveillance study of 6,496 CAP 
pathogens compared ceftaroline to comparator agents.32 
Ceftaroline was found to be eight-fold more active against 
1,340 S. pneumoniae strains than ceftriaxone. Furthermore, 
ceftaroline exhibited excellent activity against MDRSP.32,34,35 
Another group found ceftaroline to be the most active agent 
against 120 strains of cefotaxime-resistant S. pneumoniae.36 
Additionally, ceftaroline was noted to have potent   activity 
against strains with defined PBPs and murM mutations 
known to confer resistance to β-lactams.36 Similar results 
were evidenced in a susceptibility study of 891strains of 
S. pneumoniae isolated in the United States, which com-
pared ceftaroline with current available antibiotic therapies. 
Again, ceftaroline was the most effective agent tested and 
displayed a high level of activity against the subset of strains 
considered to be resistant to penicillin, macrolides, lincos-
amides, trimethoprim-sulfamethoxazole, and quinolones.31 
Likewise, in another study, ceftaroline demonstrated very 
high potency against 584 strains of Haemophilus influenzae 
and 377 strains of Moraxella catarrhalis – a degree of activity 
comparable to ceftriaxone.32 The characteristics of ceftaroline 
were tested in vivo in an experimental pneumonia rabbit 
model where subjects were inoculated with different strains 
of S.   pneumoniae. Ceftaroline was similar to ceftriaxone in 
eradicating the infection in subjects infected with penicillin 
susceptible S. pneumoniae strains; but more importantly, cef-
taroline was superior in the treatment of MDRSP strains.37
Ceftaroline is the first cephalosporin approved to have 
in vitro activity against methicillin-resistant S. aureus 
(MRSA), a characteristic that may prove to be particularly 
useful if this pathogen continues to increase in frequency. 
Large series of isolates have demonstrated bactericidal 
activity against coagulase-negative staphylococci as 
well as methicillin-susceptible and methicillin-resistant 
S. aureus.29,32 Furthermore, ceftaroline has exhibited potent 
activity against vancomycin-intermediate S. aureus (VISA), 
vancomycin-resistant S. aureus (VRSA), linezolid-resistant 
Table 1 Spectrum of microbiological coverage
Gram-positive bacteria Gram-negative bacteria
• Staphylococcus aureus (MSSA and MRSA) • Klebsiella pneumoniae
• Streptococcus pyogenes • Klebsiella oxytoca
• Streptococcus agalactiae • Escherichia coli
• Streptococcus pneumoniae • Citrobacter koseri
• Streptococcus dysgalactiae • Citrobacter freundii
• Enterobacter cloacae
• Enterobacter aerogenes
• Haemophilus influenzae
• Haemophilus parainfluenzae
• Proteus mirabilis
• Moraxella catarrhalis
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-
susceptible Staphylococcus aureus.
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Table 2 Susceptibility for ceftaroline in in vitro studies
Pathogens In vitro studies – MIC range (μg/mL)
Sader27 Ge28 Brown29 Saravolatz30 Jacobs31 Jones32 Kaushik33
S. aureus 0.25 to 2 #0.12 to 2
MRSA 0.12 to 2 0.12 to 2 0.5 to 1 #0.25 to 2 0.25 to 2
MSSA 0.03 to 0.5 #0.03 to 1 0.25 to 0.5 #0.1 to 0.5 #0.008 to 1
CA-MRSA #0.251
VISA/hVISA 0.25 to 4 0.25 to 2 #0.251 0.25 to 4
VRSA 0.5 to 1 #0.121
Streptococcus pneumoniae 0.015 to 0.5 #0.008 to 0.5 #0.008 to 0.5
Streptococcus pneumoniae 
PCN resistant
0.06 to 0.5 #0.008 to 0.5 0.015 to 0.5 #0.006 to 0.5 #0.008 to 0.5
Streptococcus pneumoniae 
PCN susceptible
#0.016 to 0.06 #0.008 to 0.12 0.015 to 0.12 #0.008 to 0.12
Streptococcus pyogenes 
Macrolide resistant
#0.008 to 0.03 0.015 to 0.5
Moraxella catarrhalis #0.016 to 012 #0.03 to 0.5 0.015 to 1 #0.008 to 1 #0.008 to 0.5
Haemophilus influenzae #0.016 to 0.25 #0.008 to 2 0.015 to 0.25 #0.008 to 0.12 #0.008 to 0.25
Klebsiella pneumoniae 0.03 to 4 #0.03 to .16 0.03 to 1 #0.008 to .16 #0.03 to 165
Escherichia coli #0.016 to 0.025 #0.03 to .16 0.015 to 16 #0.015 to .16 0.5 to .16
Enterobacter cloacae 0.03 to .32 #0.03 to .16 0.06 to 2 #0.015 to .16 #0.03 to .16
Pseudomonas aeruginosa 4 to .32 0.5 to 32 1 to .128
Abbreviations:  MIC,  minimum  inhibitory  concentration;  MRSA,  methicillin-resistant  Staphylococcus  aureus;  MSSA,  methicillin-susceptible  Staphylococcus  aureus;   
CA-MRSA, community acquired methicillin-resistant Staphylococcus aureus; VISA/hVISA, vancomycin-intermediate S. aureus/hetero-resistant VISA; VRSA, vancomycin-
resistant S. aureus; PCN, penicillin.
S. aureus (LRSA), and daptomycin-nonsusceptible S. aureus 
(DNSSA).30,38 The activity against DNSSA was confirmed in 
a study that tested ceftaroline against four different strains. 
Ceftaroline showed sustained bactericidal activity against 
three of the strains and a sustained reduction in the bacterial 
counts with respect to the fourth.39
Ceftaroline has similar microbial coverage as other third-
generation cephalosporins for gram-negative microorgan-
isms (Table 1). The potency of ceftaroline is comparable 
with ceftriaxone, ceftazidime, and piperacillin/tazobactam 
for Escherichia coli (E. coli), Klebsiella pneumoniae, and 
Enterobacter cloacae.32 However, it is important to note that 
ceftaroline, in a similar fashion to third-generation cepha-
losporins, does not have significant in vitro activity against 
extended-spectrum beta-lactamase (ESBL) producing organ-
isms, Pseudomonas sp., or atypical microorganisms.
Pharmacokinetics
The absorption of ceftaroline has been analyzed in healthy 
adults. The prodrug ceftaroline fosamil acetate (CFA) and 
inactivated ceftaroline metabolites displayed linear-dose 
kinetics.33 Additionally, ceftaroline’s concentrations were 
not associated to the duration of the dosing interval. The 
drug’s pharmacokinetic analysis is compatible with a two-
compartmental model with zero order input and first order 
elimination.40 The volume of distribution of ceftaroline is 
28.3 L (0.37 L/kg; range 0.31–0.45 L/kg) and the drug does 
not significantly bind to serum proteins, with less than 20% 
being protein-bound. CFA does not have any penetration 
into erythrocytes.33
Ceftaroline fosamil acetate is rapidly metabolized by 
phosphatases, which convert it to ceftaroline after intrave-
nous administration. The active drug then undergoes further 
conversion by hydrolysis into the inactive ceftaroline-M-1. 
The average half-life of ceftaroline and ceftaroline M-1 is 
2.6 hours and 4.5 hours, respectively.41 Of the ceftaroline 
metabolites, ceftaroline is not detected in the urine, while 
approximately 50% of the dose is excreted as active drug 
with a small portion (average 7%) excreted as ceftaroline-
M-1.41 Ceftaroline has only minimal enteric elimination. In 
patients with mild renal impairment (creatinine clearance 
[CrCl] of 50–80 mL/min), the area under the curve (AUC) 
was 25% higher and the half-life 14% longer. In patients with 
moderate renal impairment (CrCl 30–50 mL/min), the AUC 
was 50% higher. Because of these characteristics, ceftaroline 
should be used with caution in patients with moderate to 
severe renal impairment, and dosing adjustments according 
to renal function are advised.42
The dosing recommendation for intravenous   dosing 
is as follows depending on the CrCl: (1) higher than 
50 mL/min: no adjustment (600 mg every 12 hours); (2) 
30–50 mL/min: 400 mg every 12 hours; (3) 15–30 mL/min: 
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300 mg every 12 hours; (4) for patients on dialysis: 200 mg 
every 12 hours.41,43 Animal models have shown a favorable 
pharmacokinetic profile with intramuscular administration 
comparable to intravenous dosing.44,45 The absolute bio-
availability after an intramuscular dose was equivalent to 
an intravenous dose.43
Pharmacodynamics
Ceftaroline exhibits time-dependent killing. As such, the 
amount of time that the serum concentration remains above 
the minimum inhibitory concentration (MIC); (%T . MIC) 
represents the main pharmacodynamic predictor of efficacy. 
Pharmacodynamic evaluations have been performed in 
murine thigh and lung infection models.46 The results from 
this study demonstrated a minimal post-antibiotic effect 
ranging from 0.33 hours to 7.2 hours for S. pneumoniae, 
E. coli, and S. aureus.46 Additionally, ceftaroline was found 
to be bacteriostatic for staphylococci and gram-negative 
bacilli when free drug concentration exceeded the MIC for 
30% and 40% of the dosing interval, respectively.46 On the 
other hand, bactericidal activity for staphylococci and gram-
negative bacilli with ceftaroline occurred when %T . MIC 
was 50% and 60%, respectively.46
Clinical use and efficacy in CAP
The efficacy and safety of ceftaroline for the treatment of 
CAP was evaluated in the FOCUS (ceFtarOline Community-
acquired pneUmonia) trial against ceftriaxone in hospitalized 
patients with CAP. This study included two similar, Phase III, 
double-blinded, randomized, multinational, prospective trial 
designs (FOCUS 1 and FOCUS 2).47 The primary objective 
of these studies was to determine non-inferiority in clinical 
cure rates of ceftaroline compared with ceftriaxone in the 
clinically evaluable and modified intent-to-treat efficacy 
populations. Clinical cure was defined as resolution of all 
signs and symptoms of pneumonia or improvement such that 
no further antimicrobial therapy was necessary.47 Patients 
were also required to have absence of fever for 24 consecu-
tive hours with signs and symptoms of CAP returning to 
baseline levels.47
The study design for both trials involved random-
ization of patients with CAP based severity using the 
Pneumonia Outcomes Research Team (PORT) score 
of III or IV (patients that required an admission to the 
hospital for administration of intravenous antibiotics) to 
receive either 600 mg intravenously of ceftaroline every 
12 hours or one gram intravenously of ceftriaxone daily 
for 5–7 days. Importantly, the studies excluded patients 
who were not admitted to the hospital (PORT I and II) or 
directly to the intensive care unit (ICU) (PORT V). Other 
notable exclusion criteria were patients with severe renal 
impairment (CrCl # 30 mL/min), risk factors for hospital-
acquired infections, known or suspected infections with 
atypical microorganisms, risk factors or positive cultures 
for MRSA, and immunosuppression. The sole difference 
between these two studies was that the patients enrolled 
in FOCUS 1 received two doses of clarithromycin on day 
one. This additional treatment was required to enable 
enrollment in North America, where macrolide therapy is 
recommended, but to limit potential confounding of study 
drug treatment effect, it was only given during the first 
24 hours of treatment.
An integrated analysis of both trials included a total 
of 1,228 patients (ceftaroline, n = 614 versus ceftriaxone, 
n = 614). Baseline characteristics were similar between the 
groups. The study groups had the following similar baseline 
characteristics: age distribution, race, gender, comorbid 
conditions, PORT scores, white-blood cell counts, bacte-
remia, and immature band counts. The primary outcomes 
demonstrated that of the clinically evaluable patients treated 
with ceftaroline, 84.3% achieved a clinical cure, compared 
with 77.7% of patients treated with ceftriaxone (95% CI, 
1.6%–11.8%). In the modified intent-to-treat efficacy popu-
lation, clinical cure was achieved in 82.6% of the patients 
treated with ceftaroline, compared to 76.6% treated with 
ceftriaxone (95% CI, 1.4%–10.7%). The adverse effects and 
tolerability of the medications were similar in both groups. 
There were 27 reported deaths during the study; 15 (2.4%) 
in the ceftaroline group and 12 (2.0%) in the ceftriaxone 
group (Table 3).47
The most frequent isolated pathogen was S. pneumoniae, 
with a combined prevalence of 33.6% (122 isolates), which is 
consistent with the epidemiology of CAP. The clinical cure 
rates for S. pneumoniae were 85.7% (54 of 63 patients) for 
ceftaroline and 69.5% (41 of 59 patients) for ceftriaxone. Even 
though the total number of patients treated for MDRSP CAP 
was low (n = 13), ceftaroline exhibited a higher rate of clinical 
cure (4/4, 100%) compared to ceftriaxone (2/9, 22%).
Staphylococcus aureus was the second most common 
pathogen isolated with an incidence of 14.3% (52 isolates). 
The clinical cure rates for S. aureus were 72.0% (18 of 
25 patients) for ceftaroline and 55.6% (15 of 27 patients) 
for ceftriaxone. Out of the S. aureus isolates, only two were 
MRSA, and both were in the ceftriaxone study arm. The low 
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prevalence of MRSA is likely due to both a relative low fre-
quency of occurrence of this pathogen causing CAP and the 
exclusion criteria of the FOCUS 1 and FOCUS 2 studies.48
Based on the above findings, the authors concluded 
that ceftaroline was clinically non-inferior to ceftriaxone. 
Furthermore, the integrated analysis demonstrated a favor-
able trend towards ceftaroline improving clinical cure rates 
reaching statistical significance. These outcomes strongly 
support the efficacy and safety of ceftaroline treatment in 
hospitalized, non-ICU patients with CAP, but leave unan-
swered questions regarding efficacy in other populations. 
Given the exclusion criteria of these studies, data are lacking 
regarding the efficacy of ceftaroline for CAP treatment in 
patients that are immunosuppressed, require ICU admission, 
or have risk factors for MRSA and other hospital-acquired 
infections. Importantly, ceftaroline showed clinical efficacy 
for the treatment of MDRSP, but larger studies are needed 
to confirm these findings. Currently, the USA Federal Drug 
Administration (FDA) has approved ceftaroline as an option 
for the treatment of CAP.
Safety
The frequency of diarrhea, nausea, vomiting, constipation, 
transaminitis, hypokalemia, rash, and phlebitis was similar 
in patients that received ceftaroline compared to treatment 
regimens with vancomycin plus aztreonam (skin and skin 
structure studies) or ceftriaxone.47,49 Developmental toxicity 
studies performed in rats that received ceftaroline at a dose 
eight times greater than the human dose did not demonstrate 
maternal toxicity or effects on the fetus. Currently, there are 
no adequate trials evaluating the use of ceftaroline in pregnant 
women, and so it should be used with caution and then only 
when the potential benefits outweigh potential risks to the 
fetus. It has not been determined if ceftaroline is excreted 
in the human milk and caution should be exercised when 
administering this medication to a nursing woman.   Long-term 
studies evaluating carcinogenesis, mutagenesis, and effects 
on fertility have not been performed on ceftaroline.
The ecological impact of ceftaroline in human intestinal 
microflora has been evaluated after healthy subjects received 
600 mg intravenously (IV) every 12 hours for 7 days.50 In 
this study, there was no significant impact on the numbers 
of resistant E. coli, Bacteroides sp., Enterococcus sp., or 
Candida albicans strains. More importantly, no new colo-
nizing aerobic or anaerobic bacteria resistant to ceftaroline 
(MIC . 4 mg/L) were detected. Additionally, the incidence 
of Clostridium difficile infection with ceftaroline was similar 
to other cephalosporins.
Comparative advantages
As compared to other clinically available agents, ceftaro-
line exhibits low resistance rates and possesses a broader 
Table 3 Clinical cure rates comparing ceftaroline against ceftriaxone in CAP patients enrolled in the FOCUS 1 and FOCUS 2 studies
Test of cure FOCUS 1 FOCUS 2 Integrated FOCUS 1 and 2
Ceftaroline Ceftriaxone Ceftaroline Ceftriaxone Ceftaroline Ceftriaxone
Primary outcomes n/N (%)
Clinical evaluable 194/224 (86.6)* 244/291 (83.8) 193/235 (82) 166/215 (77) 387/459 (84)* 349/449 (77)
Modified intent to treat efficacy 244/291 (83) 23/300 (77) 235/289 (81) 206/273 (75) 479/580 (82)* 439/573 (76)
Secondary outcomes
Microbiologically evaluable 62/69 (89)* 54/71 (76) 69/85 (81) 57/76 (75) 131/154 (85)* 111/147 (75)
Streptococcus pneumoniae 24/27 (88.9) 20/30 (66) 35/42 (83.3) 28/40 (70) 59/69 (85.5) 48/70 (68)
Streptococcus pneumoniae 
PCN resistant
2/2 (100) 0/1 (0) 2/2 (100) 2/8 (25) 4/4 (100) 2/9 (22)
Staphylococcus aureus 8/10 (80) 9/14 (64) 10/15 (66.7) 9/16 (56) 18/25 (72) 18/30 (60)
Haemophilus influenzae 4/5 (80) 7/10 (70) 13/15 (86) 13/14 (92) 17/20 (85) 20/24 (83)
Klebsiella pneumoniae 7/8 (87) 3/5 (60) 7/7 (100) 7/8 (87) 14/15 (93) 10/13 (76)
Escherichia coli 8/8 (100) 5/7 (71) 2/4 (50) 4/6 (66) 10/12 (83) 9/13 (69)
Microbiological modified  
intent to treat efficacy
66/75 (88)* 60/80 (75) 72/90 (80) 66/88 (75) 138/165 (83) 126/168 (75)
PORT risk class III 136/150 (90)* 113/142 (79) 113/137 (82) 104/132 (78) 249/287 (86)* 217/274 (79)
PORT risk class IV 58/74 (78) 70/92 (76) 80/98 (81) 62/83 (74) 138/172 (80) 132/175 (75)
End of therapy Secondary outcomes
Clinical evaluable 197/224 (87)* 188/234 (80) 102/235 (86) 172/215 (80)
Note: *P , 0.05 when comparing ceftaroline versus ceftriax.
Abbreviations: PCN, penicillin; PORT, Pneumonia Outcomes Research Team.
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spectrum activity against common pathogens implicated 
in CAP. Furthermore, ceftaroline’s safety profile is simi-
lar to that of current antimicrobials utilized to treat these 
  infections. The most common adverse effects reported with 
ceftaroline were diarrhea, nausea and vomiting, but serious 
adverse effects, such as anaphylaxis and respiratory failure, 
were similar between the ceftaroline and comparators.47,51 
The propensity and in vitro frequency of ceftaroline to 
develop resistance with major pathogens is low.42 This was 
evidenced by multistep resistance studies.52,53 Serial passage 
studies were carried out to determine the probability of 
developing resistance to ceftaroline in isolates of S. pneu-
moniae,   Haemophilus influenzae, Moraxella catarrhalis, 
MRSA, MSSA, and S. pyogenes. These studies demon-
strated low ceftaroline MICs without the devolvement of 
clones with increased MICs.42,52,53   Spontaneous resistance 
development with vancomycin-resistant E. faecalis and 
vancomycin-susceptible E. faecalis has been demon-
strated.33,42 Although, not inferior to ceftriaxone in the 
treatment of CAP patients, ceftaroline has potent activity 
against community-acquired MRSA as well as difficult to 
treat bacterial isolates including VISA, VRSA, LRSA, and 
DNSSA.30 Since ceftaroline treats the most common CAP 
pathogens (including resistant isolates) and possesses an 
uncomplicated dosing and administration scheme, with a 
low propensity for drugs interactions, it is a good alternative 
agent for patients who do not tolerate or respond to other 
antibacterial therapies.33,42,54
Comparative disadvantages
Currently, ceftaroline has been tested only on specific 
  populations of patients (CAP in patients that require 
  hospitalization, but not ICU care, and complicated skin 
and skin structure infections). This significantly limits its 
use, not only for other types of infections, but also for use 
in patients with pneumonia with different characteristics or 
risk factors (ie, patients admitted to the ICU or on dialysis). 
Other disadvantages are that ceftaroline can only be used 
intravenously. Although intramuscular administration has 
been studied, it is currently not approved. In addition, there 
is no oral preparation of ceftaroline that could facilitate tran-
sitioning of care. Compared to ceftriaxone, ceftaroline has to 
be given twice daily instead of once a day. There have been 
also some reports of the limited stability of ceftaroline after 
mixing the compound before   administration.55 Furthermore, 
there are currently no cost-benefit studies evaluating the use 
of ceftaroline in the treatment of CAP, but the current cost of 
this medication is higher than other comparable agents. The 
cost of ceftaroline is about $41 per vial, which corresponds 
to about .$80/day. This cost is higher than the comparators 
available to treat CAP which include intravenous formula-
tions of cephalosporins and respiratory fluoroquinolones. 
However, if further studies show a benefit in MRSA pneu-
monia patients, ceftaroline might be a comparable or less 
expensive alternative compared to vancomycin or linezolid. 
Caution should be undertaken when using a newly developed 
medication, but current safety date does not preclude its use 
as it has a similar safety profile as other cephalosporins.
Even though ceftaroline has exhibited high in vitro 
potency against MDRSP, MRSA, VISA, VRSA, and 
DNSSA, and was clinically effective in treating complicated 
skin-structure and skin infections with theses pathogens, 
studies on the efficacy in CAP caused by staphylococcal 
species are lacking.51 Until studies are done evaluating other 
applications of ceftaroline, its use should be limited to the 
populations where it has shown clinical efficacy.
Future investigations
The emergence of antimicrobial resistance remains a concern 
and requires the continued development of novel agents. 
Given ceftaroline’s in vitro success in treating MRSA and 
other resistant strains of S. aureus, future studies should 
focus on the drug’s clinical impact on pneumonias and other 
infections caused by these pathogens. Additionally, the use 
of ceftaroline for the treatment of pneumonia should be 
explored in other populations, including patients admitted 
to the ICU, as well as those with septic shock, infected with 
disseminated infections or infections affecting other organs, 
and requiring renal replacement therapy.
Ceftaroline, similar to other β-lactam agents, lacks the 
ability to combat ESBL pathogens. Given ceftaroline’s wide 
coverage of gram-negative and gram-pathogens, there is 
interest in combining this antibiotic with other agents to 
provide additional pathogen coverage. Currently, there is an 
ongoing trail evaluating the combination of ceftaroline with 
NXL104, an inhibitor of β-lactamase. Preliminary murine 
models on NXL104 are promising.56 The clinical implica-
tions of this drug combination are encouraging in an era of 
increasing multi-resistant pathogen induced infections.
Conclusion
Ceftaroline, a novel fifth-generation cephalosporin, is a safe 
and effective alternative for the treatment of CAP in non-
ICU hospitalized patients. The drug’s in vitro activity has 
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exhibited high potency activity against MDRSP, MRSA, 
VISA, VRSA, and DNSSA; but studies evaluating the clini-
cal outcomes of these effects in CAP are lacking. Although 
other agents have been recently FDA approved or are under 
development, further research should continue to evaluate 
the possible applications of ceftaroline in patients with CAP 
that require ICU admission and/or have risk factors for 
MRSA and other resistant gram-positive pathogens that can 
cause pneumonia. Recent ceftaroline research is focused on 
evaluating the drug’s clinical applications for the treatment 
of infections due to other pathogens. Studies evaluating the 
combination of ceftaroline plus NXL104 have demonstrated 
activity against pathogens, such as multi-resistant gram-
negative bacteria. In a time of increasing multi-drug resistant 
infections, this research may provide additional treatment 
alternatives to the current antibiotic armamentarium.
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